Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay on the market.
HERCULES, Calif. — May 2, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay on the market. The panel can identify and quantify 48 different analytes linked to heart disease, autoimmunity and allergy, cancer, and many other conditions.
“The Bio-Plex Pro Human Cytokine Screening Panel has been validated to deliver more accurate data points within assay range than similar multiplex assays on the market,” said Ivan Huang, Bio-Rad Global Product Manager, Bio-Plex. “The ability to accurately probe both endogenous and diseased/treated samples with a single assay across a broad range of targets gives researchers tremendous insight and enables them to make actionable decisions in terms of biomarker discovery and drug development.”
To understand complex biological networks, disease states, and treatment effects, biopharma and academic researchers need to simultaneously interrogate many biomarkers present in human samples. The Bio-Plex Pro Human Cytokine Panel enables highly sensitive detection of the most often researched and biologically relevant cytokines in a single well, conserving time and resources. This panel consists of adaptive immunity cytokines, pro-inflammatory cytokines and anti-inflammatory cytokines all in a single well.
The assay provides highly sensitive detection — well below sub-picogram per milliliter range — without adding amplification steps to the workflow. The antigens and antibodies are also carefully developed in-house and tested to maximize specificity and minimize signal interference from irrelevant molecules, to enable precise and accurate quantification of multiple analytes simultaneously.
Other key benefits:
- Reproducible results — gain confidence in experiments with a robust, magnetic bead–based workflow
- Save time — the entire immunoassay can be run in less than 4 hours as opposed to other multiplex panels, which can require overnight incubation
The Bio-Plex Pro Human Cytokine Screening Panel is a ready-to-use, 1 x 96-well kit that includes premixed magnetic capture beads and detection antibodies, multiplexed standards and controls, secondary antibodies for fluorescence detection, and buffers. It is compatible with the following platforms: Bio-Plex MAGPIX Multiplex Reader, Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, LX200 Instrument, and Flexmap 3D System. Data can be managed and analyzed using Bio-Plex Manager and Bio-Plex Data Pro Software.
Please visit bio-rad.com/HumanCytokinePanel to learn more about the Bio-Plex Pro Human Cytokine Screening Panel.
Bio-Rad and Bio-Plex are trademarks of Bio-Rad Laboratories, Inc. and MAGPIX, xMAP, and Flexmap 3D are trademarks of Luminex, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact:
Bio-Rad Laboratories, Inc.
Amy Hendricksen
amy_hendricksen@bio-rad.com
510-741-4889
CG Life
Ken Li
312-532-4675
